These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 27211070)

  • 1. What can trigger the onset of Parkinson's disease - A modeling study based on a compartmental model of α-synuclein transport and aggregation in neurons.
    Kuznetsov IA; Kuznetsov AV
    Math Biosci; 2016 Aug; 278():22-9. PubMed ID: 27211070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
    Xu S; Chan P
    Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-synuclein aggregation and its modulation.
    Ghosh D; Mehra S; Sahay S; Singh PK; Maji SK
    Int J Biol Macromol; 2017 Jul; 100():37-54. PubMed ID: 27737778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading.
    Loria F; Vargas JY; Bousset L; Syan S; Salles A; Melki R; Zurzolo C
    Acta Neuropathol; 2017 Nov; 134(5):789-808. PubMed ID: 28725967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical models of α-synuclein transport in axons.
    Kuznetsov IA; Kuznetsov AV
    Comput Methods Biomech Biomed Engin; 2016; 19(5):515-26. PubMed ID: 26207359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic modeling of alpha-synuclein aggregation for the sporadic and genetic forms of Parkinson's disease.
    Raichur A; Vali S; Gorin F
    Neuroscience; 2006 Oct; 142(3):859-70. PubMed ID: 16920272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?
    Kuznetsov IA; Kuznetsov AV
    Math Biosci; 2022 Feb; 344():108754. PubMed ID: 34890628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Synuclein Intermediates α-Synuclein Neurotoxicity in Parkinson's Disease.
    Xian M; Li J; Liu T; Hou K; Sun L; Wei J
    ACS Chem Neurosci; 2024 Jul; 15(13):2445-2453. PubMed ID: 38905183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prion-Like Spreading of Alpha-Synuclein in Parkinson's Disease: Update on Models and Hypotheses.
    Jan A; Gonçalves NP; Vaegter CB; Jensen PH; Ferreira N
    Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A model of nitric oxide induced α-synuclein misfolding in Parkinson's disease.
    Stone DK; Kiyota T; Mosley RL; Gendelman HE
    Neurosci Lett; 2012 Aug; 523(2):167-73. PubMed ID: 22776646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.
    Luna E; Luk KC
    FEBS Lett; 2015 Dec; 589(24 Pt A):3749-59. PubMed ID: 26505673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified α-Synuclein.
    Chen H; Zhao YF; Chen YX; Li YM
    ACS Chem Neurosci; 2019 Feb; 10(2):910-921. PubMed ID: 30628768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid FRET Assay for the Early Detection of Alpha-Synuclein Aggregation in Parkinson's Disease.
    Yu H; Feng R; Chen F; Wu Z; Li D; Qiu X
    ACS Chem Neurosci; 2024 Apr; 15(7):1378-1387. PubMed ID: 38506367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Synuclein Trafficking in Parkinson's Disease: Insights From Fly and Mouse Models.
    Cheng J; Lu Q; Song L; Ho MS
    ASN Neuro; 2018; 10():1759091418812587. PubMed ID: 30482039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease.
    Bar-On P; Crews L; Koob AO; Mizuno H; Adame A; Spencer B; Masliah E
    J Neurochem; 2008 Jun; 105(5):1656-67. PubMed ID: 18248604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond α-synuclein transfer: pathology propagation in Parkinson's disease.
    Hansen C; Li JY
    Trends Mol Med; 2012 May; 18(5):248-55. PubMed ID: 22503115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease.
    Angot E; Brundin P
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S143-7. PubMed ID: 20082977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
    Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
    Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α-syn) oligomerization and secretion.
    von Einem B; Eschbach J; Kiechle M; Wahler A; Thal DR; McLean PJ; Weishaupt JH; Ludolph AC; von Arnim CAF; Danzer KM
    Aging (Albany NY); 2017 Jul; 9(7):1677-1697. PubMed ID: 28722658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology.
    Longhena F; Faustini G; Spillantini MG; Bellucci A
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.